These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 28476164)

  • 1. Wnt/beta-catenin pathway: modulating anticancer immune response.
    Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
    J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
    Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
    Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the role of Wnt biology in cancer.
    Mirabelli CK; Nusse R; Tuveson DA; Williams BO
    Sci Signal; 2019 Jul; 12(589):. PubMed ID: 31289213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
    Stakheev D; Taborska P; Strizova Z; Podrazil M; Bartunkova J; Smrz D
    Sci Rep; 2019 Mar; 9(1):4761. PubMed ID: 30886380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt signaling in osteosarcoma.
    Lin CH; Ji T; Chen CF; Hoang BH
    Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.
    Cui J; Jiang W; Wang S; Wang L; Xie K
    Curr Pharm Des; 2012; 18(17):2464-71. PubMed ID: 22372504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Wnt/β-catenin signaling pathway in cancer.
    Zhang Y; Wang X
    J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [WNT-β-catenin signaling pathway and its relationship with cancer].
    Ochoa-Hernández AB; Juárez-Vázquez CI; Rosales-Reynoso MA; Barros-Núñez P
    Cir Cir; 2012; 80(4):389-98. PubMed ID: 23374390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Tankyrase to Fight WNT-dependent Tumours.
    Thorvaldsen TE
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of targeting Wnt/β-catenin in colon cancer.
    Sebio A; Kahn M; Lenz HJ
    Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
    Li X; Xiang Y; Li F; Yin C; Li B; Ke X
    Front Immunol; 2019; 10():2293. PubMed ID: 31616443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs.
    Vallée A; Lecarpentier Y; Vallée JN
    Cells; 2019 Jul; 8(7):. PubMed ID: 31311204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
    Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
    Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway.
    Ma Y; Zhu B; Liu X; Yu H; Yong L; Liu X; Shao J; Liu Z
    J Exp Clin Cancer Res; 2015 Oct; 34():115. PubMed ID: 26444270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of glioma cells by inactivating Wnt/β-catenin signaling.
    Tao Q; Wu C; Xu R; Niu L; Qin J; Liu N; Zhang P; Wang C
    Cell Tissue Res; 2017 Dec; 370(3):379-390. PubMed ID: 28815294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
    Dholakia J; Scalise CB; Katre AA; Goldsberry WN; Meza-Perez S; Randall TD; Norian LA; Novak L; Arend RC
    Gynecol Oncol; 2022 Jan; 164(1):170-180. PubMed ID: 34844776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
    Dzobo K; Thomford NE; Senthebane DA
    OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Wnt/β-catenin signaling pathway in human cancers.
    Yao H; Ashihara E; Maekawa T
    Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
    Yan M; Li G; An J
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.